Premetastatic niche: Ready for new therapeutic interventions?

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Zoccoli, Alice ^a   Iuliani, Michele ^a   Pantano, Francesco ^a   Imperatori, Marco ^a   Intagliata, Salvatore ^a   Vincenzi, Bruno ^a   Marchetti, Paolo ^a,b   Papapietro, Nicola ^a   Denaro, Vincenzo ^a   Tonini, Giuseppe ^a   Santini, Daniele ^a,c  

^a Department of Medical Oncology ^*  (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

bone marrow derived cells (BMDC); cancer stem like cells (CSC); chemokine; integrin; premetastatic niche RANK RANKL

Indexed keywords

ANTIMETASTATIC AGENT; CHEMOKINE RECEPTOR CXCR4; CTCE 9908; CYTOKINE; DENOSUMAB; ERISMODEGIB; GLPG 0187; INHIBITOR OF DIFFERENTIATION 1; INTERSTITIAL COLLAGENASE; MK 0752; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PF 3084014; PROTEIN LYSINE 6 OXIDASE; R 04929097; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEMAGACESTAT; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; VOLOCIXIMAB; ZOLEDRONIC ACID;

ARTICLE; BONE MARROW CELL; BONE METASTASIS; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CELL VACUOLE; CIRCULATING TUMOR CELL; CYTOKINE RELEASE; HEMATOPOIETIC STEM CELL; HUMAN; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; NONHUMAN; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84858961972     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.656092     Document Type: Article

References (101)

1. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-2
2. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999;91:80-5 (Pubitemid 29042447)
3. Demicheli R, Abbattista A, Miceli R, et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996;41:177-85.1996
4. Riethmüller G, Klein CA. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 2001;11:307-11 (Pubitemid 32799908)
5. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93
6. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86 (Pubitemid 39457982)
7. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55 (Pubitemid 35223554)
8. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-22 (Pubitemid 43289397)
9. Saccani A, Schioppa T, Porta C, et al. p50 nuclear factor-kB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432-40 (Pubitemid 46009975)
10. Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009;4:e6562
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8 (Pubitemid 36418143)
12. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-01
13. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15 (Pubitemid 46067311)
14. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009;13:2236-52
15. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- Breast cancer cells exhibit enhanced invase properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59
16. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26 (Pubitemid 46143225)
17. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem sells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13
18. Ling LJ, Wang S, Liu XA, et al. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone. Chin Med J (Engl) 2008;121:1980-6
19. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-9
20. Draffin JE, McFarlane S, Hill A, et al. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64:5702-11
21. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6 (Pubitemid 32225831)
22. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004;14:181-5 (Pubitemid 38586743)
23. Furusato B, Mohamed A, Uhlen M, et al. CXCR4 and cancer. Pathol Int 2010;60:497-05
24. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6 (Pubitemid 37487967)
25. Turley EA, Veiseh M, Radisky DC, et al. Mechanisms of disease: epithelial-mesenchymal transition does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008;5:280-90 (Pubitemid 351594144)
26. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308
27. Radisky DC, LaBarge MA. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008;2:511-12 (Pubitemid 351729219)
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54
29. Mani SA, Guo W, Liao MJ, et al. The epithelial mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15 (Pubitemid 351636299)
30. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24 (Pubitemid 41112921)
31. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4
32. Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000;2:408-16 (Pubitemid 32223637)
33. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300 (Pubitemid 41043963)
34. Yin T, Li L. The stem cell niche in bone. J Clin Invest 2006;116:1195-01. Review
35. Wu JY, Scadden DT, Kronenberg HM. Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Miner Res 2009;24:759-64; Review
36. Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25:977-88 (Pubitemid 44894948)
37. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-12
38. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 2006;38:497-08
39. Yu XF, Huang YF, Collin-Osdoby P, et al. Stromal cell derived factor 1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase 9 (MMP9) activity, and collagen transmigration. J Bone Miner Res 2003;18:1404-18 (Pubitemid 41070795)
40. Yu XF, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase 9 activity. Connect Tissue Res 2003;44:79-84 (Pubitemid 36395426)
41. Zheng H, Fu G, Dai T, et al. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007;50:274-80 (Pubitemid 47428975)
42. Gerritsen ME, Peale FV, Wu T. Gene expression profiling in silico: relative expression of candidate angiogenesis associated genes in renal cell carcinomas. Exp Nephrol 2002;10:114-19 (Pubitemid 34293679)
43. Liang Z, Wu T, Lou H, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004;64:4302-30
44. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009;21:761-7
45. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006;116:1195-01
46. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007;28:299-307 (Pubitemid 46963141)
47. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development. Cell 2000;103:41-50
48. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6
49. Mori K, Le Goff B, Charrier C, et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: New insights in the prostate cancer bone metastasis process. Bone 2007;40:981-90 (Pubitemid 46386537)
50. Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2010;226:780-4
51. Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 2011;6:e19234
52. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25:541-9 (Pubitemid 46071863)
53. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-25 (Pubitemid 41614462)
54. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
55. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
56. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giantcell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80
57. Pecheur I, Peyruchaud O, Serre CM, et al. Integrin alphanubeta3 expression confers on tumor cells a greater propensity to metastasixe to bone. FASEB J 2002;16:1266-8
58. Clezardin P. Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 2009;9:801-6
59. Bauerle T, Komljenovic D, Merz M, et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer 2011;128:2453-62
60. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
61. Available from: www.clinicaltrials.gov/ct2/show/NCT01313598?term= GLPG0187&rank=1
62. Available from: www.clinicaltrials.gov/ct2/show/NCT00131651?term=ATN- 161&rank=2
63. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-05
64. Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, et al. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 1997;230:111-20 (Pubitemid 27187546)
65. Martin-Thouvenin V, Gendron MC, Hogervorst F, et al. Phorbol ester-induced promyelocytic leukemia cell adhesion to marrow stromal cells involves fibronectin specific alpha 5 beta 1 integrin receptors. J Cell Physiol 1992;153:95-02
66. Korah R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22 (Pubitemid 38856923)
67. Available from: www.clinicaltrials.gov/ct2/show/NCT00100685?term= volociximab&rank=7
68. Available from: www.clinicaltrials.gov/ct2/show/NCT00516841?term= volociximab&rank=10
69. Spinella-Jaegle S, Rawadi G, Kawai S, et al. Sonic hedgehog increases the commitment of pluripotent mesenchymal cells into the osteoblastic lineage and abolishes adipocytic differentiation. J Cell Sci 2001;114:2085-94 (Pubitemid 32586633)
70. Shimoyama A, Wada M, Ikeda F, et al. Ihh/Gli2 signaling promotes osteoblast diff erentiation by regulating Runx2 expression and function. Mol Biol Cell 2007;18:2411-18 (Pubitemid 47025707)
71. Available from: www.clinicaltrials.gov/ct2/show/NCT01350115?term= lde+225&rank=8
72. Available from: www.clinicaltrials.gov/ct2/show/NCT01327053?term= lde+225&rank=7
73. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6 (Pubitemid 29291335)
74. Nobta M, Tsukazaki T, Shibata Y, et al. Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated notch1 signaling. J Biol Chem 2005;280:15842-8 (Pubitemid 40616705)
75. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67 (Pubitemid 37328814)
76. Kunnimalaiyaan M, Chen H. Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors. Oncologist 2007;12:535-42 (Pubitemid 350012116)
77. Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009;152:479-96
78. Pannuti A, Foreman K, Rizzo P, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52
79. Laoukili J, Kooistra MR, Br-as A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-36 (Pubitemid 40268127)
80. Pilarsky C, Wenzig M, Specht T, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004;6:744-50 (Pubitemid 40041492)
81. Liu M, Dai B, Kang SH, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006;66:3593-602
82. Bektas N, Haaf A, Veeck J, et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008;8:42-50
83. Wang IC, Chen YJ, Hughes D, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005;25:10875-94 (Pubitemid 41747132)
84. Park HJ, Costa RH, Lau LF, et al. Anaphasepromoting complex/cyclosome- Cdh1-mediated proteolysis of the forkhead box transcription factor is critical for regulated entry into S phase. Mol Cell Biol 2008;28:5162-71
85. Park HJ, Carr JR, Wang Z, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 2009;28:2908-18
86. Kwok JM, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010;8:24-34
87. Carr JR, Park HJ, Wang Z, et al. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010;70:5054-63
88. Wang Z, Banerjee S, Kong D, et al. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007;67:8293-300 (Pubitemid 47395167)
89. Kalinichenko VV, Major ML, Wang X, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004;18:830-50 (Pubitemid 38480894)
90. Gusarova GA, Wang IC, Major ML, et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007;117:99-111 (Pubitemid 46048457)
91. Park HJ, Gusarova G, Wang Z, et al. Deregulation of FoxM1b leads to tumourmetastasis. EMBO Mol Med 2011;3:21-34
92. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44
93. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72 (Pubitemid 36258816)
94. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002;62:4478-83 (Pubitemid 34827311)
95. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011;21:139-46
96. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44
97. Yan HH, Pickup M, Pang Y, et al. Gr-1 +CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010;70:6139-49
98. Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95 (Pubitemid 44264090)
99. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006;20:847-56
100. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006;55:808-18
101. Fizazi K, Carducci M, Smith M. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22